Document 0750
 DOCN  M9550750
 TI    Use of preventive interventions by persons infected with type-1 human
       immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study
       Group.
 DT    9505
 AU    Glassroth J; Jordan M; Wallace JM; Kvale PA; Follmann DA; Rosen MJ;
       Reichman LB; Mossar M; Hopewell PC; Division of Pulmonary Medicine,
       Northwestern University Medical; School, Chicago, IL.
 SO    Am J Prev Med. 1994 Sep-Oct;10(5):259-66. Unique Identifier : AIDSLINE
       MED/95151347
 AB    Measures aimed at preventing complications and slowing progression of
       type-1 human immunodeficiency virus (HIV-1) can potentially reduce
       morbidity. Although little is known about the use of such measures, such
       data are critical for program planning. This study was performed to
       quantify the frequency and patterns of use for such interventions. We
       enrolled 1,171 persons infected with HIV, but without an acquired
       immunodeficiency syndrome (AIDS) defining diagnosis, in a multicenter
       prospective study of the pulmonary complications of HIV infection.
       Participants were homosexual/bisexual men, injection drug users (IDUs),
       or female sexual contacts of HIV-infected men. Centers were
       university-based and geographically dispersed across the United States.
       Standardized questionnaires were administered on entry and at
       three-month or six-month intervals; we correlated use of general and
       HIV-related preventive measures before entry and during the first three
       years in study with clinical/epidemiologic characteristics. Overall use
       of preventive interventions was low; only one third of study entrants
       had used such measures. Use was greatest among those with advanced HIV
       infection, but only half used preventive measures on entry; IDUs were
       less likely than homosexuals to use these services. Although use of
       interventions such as anti-Pneumocystis and antiretroviral agents
       increased during study participation, general measures such as
       pneumococcal vaccine and tuberculosis prophylaxis were used by less than
       30% of those eligible for use. Among IDUs, cumulative use of these
       measures remained below 20% during the first three years of this study.
       We conclude that HIV-infected persons underuse preventive interventions,
       particularly general measures.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Adolescence  Adult  Antiviral Agents/THERAPEUTIC USE  AIDS Serodiagnosis
       Bisexuality  Comparative Study  CD4 Lymphocyte Count
       Dapsone/THERAPEUTIC USE  Drug Combinations  Female  Homosexuality, Male
       Human  *HIV Infections/COMPLICATIONS/IMMUNOLOGY  *HIV-1  Male  Middle
       Age  Pentamidine/THERAPEUTIC USE  Pneumonia, Pneumocystis
       carinii/PREVENTION & CONTROL  Preventive Health Services/*UTILIZATION
       Prospective Studies  Pyrimethamine/THERAPEUTIC USE  Questionnaires
       Risk-Taking  Socioeconomic Factors  Substance Abuse, Intravenous
       Sulfadoxine/THERAPEUTIC USE  Support, U.S. Gov't, P.H.S.
       Trimethoprim-Sulfamethoxazole Combination/THERAPEUTIC USE  JOURNAL
       ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).